Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda’s TAK-755 Shows Promising PIII Interim Data for Ultra-Rare Blood Clotting Disorder
Takeda Pharmaceutical’s TAK-755, an enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP), demonstrated favorable efficacy in a pre-planned interim analysis of a pivotal PIII study including Japan, the company said on January 5. cTTP is an ultra-rare subtype of…
To read the full story
Related Article
- Takeda Scores 1st US Nod for Ultra-Rare Blood Clotting Disorder
November 13, 2023
- Takeda’s cTTP Therapy Gets Priority Review in US
May 18, 2023
BUSINESS
- SanBio to Move All Akuugo Manufacturing to Minaris’ Yokohama Site
September 1, 2026
- Merck KGaA to Consolidate Japan Life Science Labs at Haneda Hub
September 1, 2026
- FDA Approves Takeda’s PV Drug Mimrylo
September 1, 2026
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…